Point72 Asset Management L.P. Has $16.84 Million Stake in Bruker Co. (NASDAQ:BRKR)

Point72 Asset Management L.P. cut its holdings in Bruker Co. (NASDAQ:BRKR - Free Report) by 57.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 243,796 shares of the medical research company's stock after selling 327,776 shares during the quarter. Point72 Asset Management L.P. owned about 0.16% of Bruker worth $16,837,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BRKR. First Horizon Advisors Inc. boosted its holdings in shares of Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company's stock valued at $25,000 after buying an additional 218 shares during the period. True Wealth Design LLC boosted its stake in Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock worth $36,000 after purchasing an additional 510 shares during the period. UMB Bank n.a. boosted its stake in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company's stock worth $46,000 after purchasing an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Bruker in the 2nd quarter valued at about $52,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company's stock valued at $60,000 after purchasing an additional 388 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Stock Performance

Shares of BRKR traded up $0.48 during mid-day trading on Friday, reaching $58.96. The company's stock had a trading volume of 1,094,026 shares, compared to its average volume of 1,515,329. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. The stock has a market cap of $8.94 billion, a P/E ratio of 28.35, a PEG ratio of 3.99 and a beta of 1.18. Bruker Co. has a 1-year low of $48.07 and a 1-year high of $94.86. The business has a 50-day simple moving average of $59.61 and a two-hundred day simple moving average of $63.48.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). The company had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company's revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period last year, the firm earned $0.74 earnings per share. As a group, equities research analysts anticipate that Bruker Co. will post 2.4 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.34%. The ex-dividend date of this dividend is Monday, December 2nd. Bruker's payout ratio is 9.62%.

Insider Transactions at Bruker

In other news, CEO Frank H. Laukien acquired 100,000 shares of the firm's stock in a transaction on Monday, November 18th. The shares were purchased at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the acquisition, the chief executive officer now directly owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This represents a 0.26 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 28.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

BRKR has been the subject of a number of research reports. Citigroup decreased their price objective on Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Wells Fargo & Company lowered their price objective on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a report on Wednesday, November 6th. Wolfe Research cut shares of Bruker from an "outperform" rating to a "peer perform" rating in a report on Monday, September 30th. Barclays decreased their target price on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. Finally, TD Cowen reduced their price objective on shares of Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research note on Wednesday, November 6th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Bruker has an average rating of "Moderate Buy" and an average price target of $79.36.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.